Dexcom stock forecast 2025 analysts tracking Dexcom stock forecast

Analysts tracking Dexcom stock forecast 2025 expect strong performance in North America and EU markets, aided by regulatory approvals and insurance coverage expansion for glucose monitoring solutions. The company’s U.S. sales declined 2% in the quarter to $701.9 million, compared to the same period a year ago. U.S. revenues (73% of total revenues) increased 15% on a year-over-year basis to $841 million. International revenues (27%) improved 16% (14% on an organic basis) year over year to $316.1 million. For growth investors, Dexcom stock forecast 2025 is supported by continued expansion in subscription models, creating steady ARR (Annual Recurring Revenue).